Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors

Pharmacogenetics

Volumn 13, Issue 11, 2003, Pages 661-674

  Hebert, Mary F ^a   Dowling, Amy L S ^a   Gierwatowski, Cynthia ^a   Lin, Yvonne S ^a   Edwards, Karen L ^a   Davis, Connie L ^b   Marsh, Christopher L ^b   Schuetz, Erin G ^c   Thummel, Kenneth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cyclosporine; Drug transporter; Genetic polymorphism; Nephrotoxicity; P glycoprotein; Tacrolimus

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; BENAZEPRIL; CALCINEURIN INHIBITOR; CANDESARTAN; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; DILTIAZEM; ENALAPRIL; FLUCONAZOLE; FOSINOPRIL; ITRACONAZOLE; KETOCONAZOLE; LISINOPRIL; LOSARTAN; MULTIDRUG RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINAPRIL; VANCOMYCIN;

ABCB1 GENE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; EVALUATION; FEMALE; GENE; GENETIC CODE; GENOTYPE; GRAFT VERSUS HOST REACTION; HETEROZYGOSITY; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX RATIO;

CALCINEURIN; CASE-CONTROL STUDIES; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, MDR; GENOTYPE; HOMOZYGOTE; HUMANS; INCIDENCE; KIDNEY DISEASES; LIVER TRANSPLANTATION; MALE; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; WASHINGTON;

EID: 1542373607     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200311000-00002     Document Type: Article

References (52)

1. Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: a cohort study. Lancet 2002; 359:287-293.
2. Neuberger J. Liver transplantation. J Hepatol 2000; 32:198-207.
3. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58:170-178.
4. Moutabarrik A, Ishibashi M, Fukunaga M, Kameoka H, Kawaguchi N, Takano Y, et al. FK506-induced kidney tubular cell injury. Transplantation 1992; 54:1041-1047.
5. Copeland KR, Yatscoff RW. Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells. Transplantation 1992; 53:640-645.
6. Healy E, Dempsey M, Lally C, Ryan MP. Apoptosis and necrosis: mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 1998; 54:1955-1966.
7. Hortelano S, Castilla M, Torres AM, Tejedor A, Bosca L. Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells. J Am Soc Nephrol 2000; 11:2315-2323.
8. Mihatsch MJ, Thiel G, Ryffel B. Cyclosporine nephrotoxicity. Adv Nephrol Necker Hosp 1988; 17:303-320.
9. Finn WF. FK506 nephrotoxicity. Ren Fail 1999; 21:319-329.
10. Abrass CK, Berfield AK, Stehman-Breen C, Alpers CE, Davis CL. Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies. Am J Kidney Dis 1999; 33:11-20.
11. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268:6077-6080.
12. Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN. Expression of ABCB1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 1997; 77:284-289.
13. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97:3473-3478.
14. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the ABCB1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12:437-450.
15. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of ABCB1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4:397-410.
16. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant ABCB1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
17. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the ABCB1 gene on expression level of ABCB1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002; 71:297-303.
18. Morita Y, Sakaeda T, Horinouchi M, Nakamura T, Kuroda K, Miki I, et al. ABCB1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 2003; 20:552-556.
19. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. ABCB1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18:1400-1404.
20. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359:30-36.
21. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human ABCB1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11:293-298.
22. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al. ABCB1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002; 53:526-534.
23. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, et al. Role of human ABCB1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72:209-219.
24. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, et al. ABCB1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54:610-616.
25. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein ABCB1 gene. Clin Pharmacol Ther 2002; 72:584-594.
26. von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47:1048-1052.
27. Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, et al. The effect of CYP3A5 and ABCB1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43:555-564.
28. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in ABCB1 and CYP3A4 genes in Asians and the influence of ABCB1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13:89-95.
29. Anglicheau D, Verstuyft C, Laurent-Puig P, Becquemont L, Schlageter MH, Cassinat B, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14:1889-1896.
30. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and ABCB1 gene polymorphisms. Am J Transplant 2003; 3:477-483.
31. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human ABCB1 gene using a vaccinia virus expression system. Mol Pharmacol 2002; 62:1-6.
32. Morita N, Yasumori T, Nakayama K. Human ABCB1 polymorphism: G2677T/A and C3435T have no effect on ABCB1 transport activities. Biochem Pharmacol 2003; 65:1843-1852.
33. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. ABCB1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11:217-221.
34. Garcia-Closas M, Egan KM, Abruzzo J, Newcomb PA, Titus-Ernstoff L, Franklin T, et al. Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash. Cancer Epidemiol Biomarkers Prev 2001; 10:687-696.
35. Lum A, Le Marchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev 1998; 7:719-724.
36. Ott J. Detection of rare major genes in lipid levels. Hum Genet 1979; 51:79-91.
37. Lewis P, Zaykin D. Genetic Data Analysis: Computer program for the analysis of allelic data. Version 1.0 (d16c). Free program distributed by the authors over the internet from http://lewis.eeb.uconn.edu/lewishome/software. html 2001.
38. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter ABCB1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174.
39. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
40. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, et al. Significant genetic linkage of ABCB1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002; 19:1581-1585.
41. Garcia del Moral R, O'Valle F, Andujar M, Aguilar M, Lucena MA, Lopez-Hidalgo J, et al. Relationship between P-glycoprotein expression and cyclosporin A in kidney. An immunohistological and cell culture study. Am J Pathol 1995; 146:398-408.
42. Seliger SL, Davis C and Stehman-Breen C. Gender and the progression of renal disease. Curr Opin Nephrol Hypertens 2001; 10:219-225.
43. Cowley BD, Jr., Rupp JC, Muessel MJ, Gattone VH, 2nd. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis 1997; 29:265-272.
44. Bayliss DA, Viana F, Kanter RK, Szymeczek-Seay CL, Berger AJ, Millhorn DE. Early postnatal development of thyrotropin-releasing hormone (TRH) expression, TRH receptor binding, and TRH responses in neurons of rat brainstem. J Neurosci 1994; 14:821-833.
45. Lown KS, Mayo RR, Leichtman AB, Hsiao H-L, Turgeon K, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (ABCB1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62:248-260.
46. Lan LB, Dalton JT, Schuetz EG. ABCB1 limits CYP3A metabolism in vivo. Mol Pharmacol 2000; 58:863-869.
47. Norris KC, Agodoa LY. Race and kidney disease: the scope of the problem. J Natl Med Assoc 2002; 94:1S-6S.
48. Nzerue CM, Demissochew H, Tucker JK. Race and kidney disease: role of social and environmental factors. J Natl Med Assoc 2002; 94:28S-38S.
49. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35:333-346.
50. Pilmore HL, Dittmer ID. Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant 2002; 16:191-195.
51. Swart N, Botha J, Tandon V, Michaels P, Pontin AR, Halkett J, et al. Can three-times-a-day cyclosporine Neoral avoid cyclosporine toxicity in renal transplant recipients? A pharmacokinetic study. Transplant Proc 2001; 33:3140-3141.
52. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2:436-442.